Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Economic evaluations of interventions against viral pandemics: a scoping review

M.K. Rasmussen a,*, C. Kronborg b, I. Fasterholdt a, K. Kidholm a

a Centre for Innovative Medical Technology, Odense University Hospital, And Department of Clinical Research, University of Southern Denmark, Denmark
b Department of Economics, University of Southern Denmark, Denmark

Abstract

Objectives: The COVID-19 pandemic has led to suggestions that cost-effectiveness analyses should adopt a broader perspective when estimating costs. This review aims to provide an overview of economic evaluations of interventions against viral pandemics in terms of the perspective taken, types of costs included, comparators, type of economic model, data sources and methods for estimating productivity costs.

Study design: Scoping literature review.

Methods: Publications were eligible if they conducted a cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis or cost-minimisation analysis and evaluated interventions aimed at viral pandemics or for patients infected with viral pandemic disease. We searched PubMed, Embase and Scopus for relevant references and charted data from the selected full-text publications into a predefined spreadsheet based on research sub-questions, summary tables and figures.

Results: From 5410 references, 36 full-text publications fulfilled the inclusion criteria. The economic evaluations were mainly model based and included direct medical costs of hospital treatment. Around half of the studies included productivity costs and the proportion of total costs attributed to productivity costs ranged from 10% to 90%, depending on estimation methods, assumptions about valuation of time, type of intervention, severity of illness and degree of transmission.

Conclusions: Economic evaluations of interventions against viral pandemics differed in terms of estimation methods and reporting of productivity costs, even for similar interventions. Hence, the literature on economic evaluations for pandemic response would benefit from having standards for conducting and reporting economic evaluations, especially for productivity costs.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of The Royal Society for Public Health. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

Decision-makers involved in setting priorities for health care budgets need reliable evidence on the costs and effects of alternative interventions. This is often provided through cost-effectiveness analyses that compare the costs of two or more alternative interventions relative to their health effects. To ensure that cost-effectiveness analyses are comparable and are based on the same type of information about resource use and effectiveness of health interventions, guidelines for conducting cost-effectiveness analyses have been produced.

Reviews on guidelines for health economic evaluations have identified consensus on key methodological principles, such as the types of economic evaluation to be used, the time horizon for analysis, relevant health outcome measures and use of sensitivity analyses. However, the reviews also identify aspects that lack a common understanding; for example, the study perspective, which costs are included, comparators, type of economic model, data sources and methods for estimating productivity costs. Pandemic diseases present additional challenges for cost-effectiveness analyses because of their wide consequences for society as a whole. Pandemic diseases are highly contagious compared with other diseases and the measures for controlling them (such as lockdown or immunisation programmes) also impact people who are not infected with the disease, including the ability to work and study. In addition, a country's limited ability...
to trade can have serious economic consequences. The COVID-19 pandemic resulted in a real gross domestic product (GDP) growth rate in Q2 2020 of −9.4% in the US and −11.9% in the EU.

In terms of the COVID-19 pandemic, some argue that a broader perspective should be adopted in economic evaluations as a new intervention against a viral pandemic is likely to impact not only the people becoming ill or receiving treatment but also the surrounding society. A broader perspective would ensure that all costs and benefits of an intervention are included in the health economic evaluation and that decision-makers are fully informed about the costs and consequences. Although the usual economic evaluation principles remain unchanged within the context of the COVID-19 pandemic, additional aspects to be considered include ‘fear of contagion, severity of illness, insurance value, and innovation and its spill over effects’ as well as ‘the broader benefits of restoring economic and social activity’.

One of the implications of taking a broader perspective is the inclusion of productivity costs, which can be defined as ‘the costs associated with lost or impaired ability to work or to engage in leisure activities due to morbidity and lost economic productivity due to death’. The term ‘indirect costs’ has been used similarly as it can include temporary absence from work due to illness, reduced working capacity due to illness and disability, or lost productivity due to early death. There seems to be a lack of consensus in guidelines on whether productivity costs should be included and a lack of agreement on the calculation of lost productivity costs. Health economic aspects of pandemics have been described in systematic reviews of pharmaceutical interventions, such as vaccination and antiviral treatment, and of non-pharmaceutical interventions, such as lockdowns, closing borders or schools, screening, isolating symptomatic individuals and contact tracing, and social distancing. The aims of these studies were to summarise evidence and find cost-effective alternatives, to provide an evidence base to inform economic evaluations and health technology assessments of COVID-19 treatments, or to investigate the use of productivity costs in health economic evaluations of vaccine programmes and drugs. Although not restricted to viral pandemic disease, vaccine and immunisation programmes often target viral disease and recent reviews have reported on the inclusion of productivity costs in economic analyses. However, we have not been able to find reviews describing estimation of productivity costs or indirect costs in economic analyses of interventions against viral pandemics.

Therefore, the objective of this study was to provide an overview of economic evaluations of interventions against viral pandemics in terms of the perspective taken, types of costs included, comparators, type of economic model, data sources and methods for estimating productivity costs. This review provides researchers, policymakers and service providers with information about applied economic methods for evaluation of interventions against viral pandemics and suggests priorities for further research.

Methods

A scoping review was conducted to obtain an overview of existing economic evaluations of interventions against viral pandemics. A scoping review can assess a broad research question to identify and map the available evidence and it can result in detailed descriptions of study methodologies.

The specific subquestions in this scoping review were as follows:

- Which types of economic evaluations have been conducted for interventions against viral pandemics?
- Which types of interventions have been examined?
- Which perspectives have been used when measuring costs?
- Which types of study design have been used for estimation of costs?
- Which data sources have been used?
- Which types of costs have been included?
- How were productivity costs or indirect costs included?

Protocol and registration

The current review followed the updated methodological guidance for conduct of scoping reviews by Peters et al. and was reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist (see Supplementary file S1). The scoping review was based on an a priori defined protocol, as recommended and this can be accessed through the Open Science Framework (see link in Supplementary file S2).

Eligibility criteria

The Participants, Concept and Context (PCC) framework guided the eligibility criteria. The review included fully available publications in peer-reviewed journals. The year of publication was not limited as relevant papers from earlier pandemics were found. Primary research was preferred (i.e., not review articles or meta-analyses) and the analysis should be conducted with a health care or societal perspective. The study searched for articles with the following PCC criteria:

Participants: patients with emerging infectious virus causing outbreaks or pandemics (i.e., Ebola, Sika, SARS, MERS, H1N1, H5N1, or COVID 19) or a pandemic virus scenario.

Concept: cost-effectiveness analysis (CEA), where results were expressed in monetary units per case averted; cost-utility analysis (CUA), where results were expressed in monetary units per quality-adjusted life-years (QALYs) or disability-adjusted life-years (DALYs); cost-benefit analysis (CBA) or cost (minimisation) analysis, where results were expressed as an intervention’s total saving or loss in monetary units.

Context: all contexts (i.e., all countries of origin) were included; however, the context should relate to health interventions and the perspective should be broader than the budget impact for a single hospital.

Information sources

The search was conducted in PubMed, EMBASE and Scopus, which are databases that include articles describing medical and health economic outcomes research.

Search strategy

The search strategy was developed using two databases, and the final search was conducted in all three databases, in accordance with guidelines. A preliminary search was conducted in PubMed and EMBASE using peer-reviewed clinical expert searches on relevant disease terms and costs. The complete search strategy is provided in Supplementary file S3.
Selection of sources of evidence

Studies were selected in two steps following the inclusion and exclusion criteria listed in Table 1.

Two reviewers (MKR and IF) conducted the selection; MKR first screened titles and abstracts using the Covidence online platform and IF mainly assisted in sorting full-text references and in extracting results. Full-text articles were then screened by both reviewers independently. This was performed in Endnote as some of the full-text articles could not be uploaded to Covidence due to copyright regulations. Disagreements were solved by discussion.

Data charting process

Full-text articles that were deemed relevant were examined and their data were entered into a predefined charting form. The following data were extracted: author and year, country and type of intervention, type of economic evaluation, study population, outcome measures, structure of economic model if relevant, perspective taken, types of costs assessed, measurement of productivity costs or indirect costs, and sources of data. The data chart was analysed using frequency tables, bar graphs and/or narrative summaries according to the focus of the research subquestions.

Results

This study identified 5410 references and, after screening of titles, abstracts and full-text, 36 articles were included in the review (see Fig. 1). The 36 articles were published between 2008 and 2021, and their main characteristics are summarised in Table 2.

All continents were represented, but over half of the studies were from North America (28%) and Europe (31%). Participants were mainly patients with COVID-19 (50%) or H1N1 (31%). The full data chart is available in Supplementary file S4.

The following sections present results on the research subquestions.

Types of economic evaluations

Cost effectiveness was reported in 22 studies (61%),11–55 four (11%) stated cost benefit,55–59 two (4%) a cost utility,33,55,60–62 three (8%) a cost-minimisation analysis55,63 and five (14%) reported multiple analyses.53–55,60,66

Types of interventions

The interventions can be split into two groups according to World Health Organisation (WHO) objectives for epidemics:67 (a) intervention strategies to suppress transmission; and (b) interventions to optimise care for patients with confirmed epidemic disease. Twenty-three studies (64%) analysed interventions to suppress transmission. These included use of face masks,50,65 insectoid-threatened nets,48 increased access to contraception,38,48 suppression policies,52 lockdown,44,57 mitigation and movement restriction policies,53,55 hand hygiene,30 school closure,34,49,50,56,63 workplace non-attendance,15,63 community contact reduction,15,63 social distancing,34,58 testing,32,36,46 and isolation strategies.44 Eight studies (22%) analysed interventions for patients with confirmed epidemic disease. These comprised changes in organisation of medical treatment31,43,47,53 and treatment with specific pharmaceuticals.37,46,60,66 Five studies (14%) examined interventions in both of the WHO defined groups.35,39,45,64,66

Perspective used when measuring costs

A societal perspective was stated in nine (25%) studies and a healthcare provider perspective in 12 (33%) studies. Four (11%) studies provided results from both perspectives. Nine studies did not state a perspective, but six (17%) included parameters referring to a societal perspective. A public payer perspective was used either alone or combined with private payer in two (6%) studies.

Study designs for cost estimation

Overall, 32 studies (89%) were model based, two studies were based on clinical studies59,64 and two studies had no described study design. In 15 (42%) studies, expected values were derived from a transmission model (e.g., the SEIR [Susceptible, Exposed, Infected, Recovered] Model) and thereafter attached to costs. Decision trees were used in 10 (28%) studies; this was alongside either Markov or other simulation models in three (8%) studies.

Data sources

Nineteen studies included estimates acquired from published literature.34–37,39,40,46–52,55–57,60–63,66 National or official statistical resources were used in 17 studies.31,34,36,40,41,43–45,47,49,50,54,56–58,60,66 Five studies used aggregate or patient-level data from local hospital resources.37,42,46,64 A few studies included prices from private insurance companies38,43 or market prices,42,60,64 questionnaires,59 or interviews with individuals (e.g., patients, household and healthcare personnel)59,64

Types of costs

Costs were grouped into direct health care costs, (89%) intervention costs, (69%) productivity costs, (58%) direct costs to the patient (11%) and direct non-health care costs (14%). Fig. 2a–c presents the most common types of costs in more detail; all cost data are available in Supplementary file S5 (Tables S2d–e).

Productivity costs or indirect costs

Productivity costs were included in 21 (58%) studies; often measured as costs of lost labour incurred by the patient due to illness or premature death (25% and 11%), as absenteeism of
relatives, close contacts and teachers (14%) but also, in some studies (11%), not explained further.

Six studies included daily wages of parents or relatives absent from work to take care of healthy or ill children.35,49,50,56,63,65 Two studies analysed different testing strategies and included loss of salary for close contacts (e.g., during household quarantine).32,55 One study included costs of work delay plus transportation for family members of sick individuals.59

Two studies included productivity costs for the health care sector as costs of quarantine and sick leave in terms of income for personnel in the hospital ward.33,42

Zala et al. modelled the cost effectiveness of suppression policies. These included productivity costs based on a macroeconomic model in which a pandemic influences GDP through (i) a reduced labour supply owing to death, illness (i.e., direct absenteeism), school closures and prophylactic absenteeism; (ii) consumption shocks owing to illness and precautionary avoidance; and (iii) modest investment deferment.52

Four studies (11%)43,59,62,63 stated a specific approach to value productivity: the human capital approach. In this approach, income acts as a proxy for the production value of the individual.1 Thirteen studies (36%) included productivity costs by multiplying days of absence due to illness, mortality or interventions by average income, GDP per capita/day or similar value per day. These studies did not state a specific approach, but their method of valuation was similar to the human capital approach.32,33,41,42,44,49,50,52,56,61,64,65 Three studies (8%) did not explain their approach nor method of valuation.39,54,58

Different assumptions were applied when estimating productivity costs. Studies analysing school closure most often included productivity costs of at least one parent, but Brown et al. assumed that only parents of children aged 6–11 years would incur

Fig. 1. Flow diagram of selection of sources of evidence.
production loss due to absenteeism from work. Neilan et al. assumed that a day in self-isolation would only halve productivity as some people would be able to work from home while moderately ill or taking care of an ill child. Kelso et al. assumed that a day in self-isolation would only halve productivity, which arose from mortality at a young age or from widely applied interventions, such as lockdowns. Severity of illness and degree of transmission were also contributing factors. The result of each cost-effectiveness analysis may be impacted by the approach used for measuring productivity costs. For example, placing a zero value on the time of older people implicitly gives a higher weight to interventions aimed at the working population who would incur productivity costs from illness while older people would not. Another example is deciding whose productivity costs should be measured. Some studies included productivity costs for the patient only or for the relatives. A few studies used the human capital approach for estimating productivity costs and although most other studies did something similar, they did not report a specific approach. The inconsistency in estimating costs, particularly productivity costs, is a challenge for decision-makers when selecting which interventions to implement. To improve consistency in methods and reporting of cost-effectiveness analyses, an updated guideline is needed specifically for interventions aimed at viral pandemics.

**Study limitations**

This review excluded studies of immunisation programmes as these were described in two recent systematic reviews. Vaughan et al. reviewed 68 costing studies and found inconsistent practices in reporting on types of immunisation costs, and that vaccine and delivery cost details were frequently not reported. The authors also reported insufficient methodological detail on data analysis and provided a checklist with specific guidance on how to write up a costing study in the field of immunisation economics. Yuasa et al. reviewed 208 studies and found that most of the studies that included productivity costs only considered patients’ absenteeism, while ignoring time lost by caregivers. The approach used to estimate productivity losses/gains was not commonly reported or not sufficiently detailed, but this may be partly due to varying country guidelines. Similarly, the current scoping review found that the impact and method of calculation of productivity costs was sometimes unclear or not reported.

Cost of illness studies were not included because this review was limited to economic evaluations as defined by Drummond et al.; thus, some relevant information might be omitted as a result.

**Conclusions**

The current scoping review showed that economic evaluations of interventions against viral pandemics may include productivity costs for both ill and non-ill individuals. In several studies, costs to parents or relatives were included, but also productivity losses within the health care sector and on a societal level were sometimes described. The estimation methods and reporting of productivity costs differed, even for similar interventions. The conclusion of a cost-effectiveness analysis can be greatly impacted by the approach used for measuring productivity costs, and this poses a challenge to decision-makers facing the choice of which

---

Table 2

Characteristics of included studies.

| Characteristic | No. of studies | % |
|---------------|---------------|---|
| Origin (Continent) | | |
| Global | 1 | 3% |
| Oceania | 1 | 3% |
| South America | 2 | 6% |
| Africa | 4 | 11% |
| Asia | 7 | 19% |
| North America | 10 | 28% |
| Europe | 11 | 31% |
| Disease | | |
| Ebola | 2 | 6% |
| Zika | 2 | 6% |
| Pandemic Influenza scenario | 3 | 8% |
| H1N1 (pandemic influenza A) | 11 | 31% |
| COVID-19 | 18 | 50% |
| Study type | | |
| Cost-minimisation & ‘ACER’ cost-effectiveness | 1 | 3% |
| Cost-effectiveness & cost-benefit | 1 | 3% |
| Cost-effectiveness & return on investment-analysis | 1 | 3% |
| Cost-utility & cost-effectiveness | 2 | 6% |
| Cost-utility | 2 | 6% |
| Cost-minimisation analysis | 3 | 8% |
| Cost-benefit | 4 | 11% |
| Cost-effectiveness | 22 | 61% |
| Study design | | |
| Patient simulation model (SEIR) with attached costs | 15 | 42% |
| Decision tree | 10 | 28% |
| Decision tree and Markov | 2 | 6% |
| Decision tree and simulation model | 1 | 3% |
| Simulation model, e.g., Monte Carlo simulation | 4 | 11% |
| Others (survey, micro costing, not described) | 4 | 11% |
| Perspective | | |
| Societal perspective | 9 | 25% |
| Healthcare provider perspective | 12 | 33% |
| Health care and societal perspective | 4 | 11% |
| Public payers’ perspective | 1 | 3% |
| Combined health sector perspective (public and private) | 1 | 3% |
| Not explicitly given (societal perspective) | 6 | 17% |
| Not explicitly given | 3 | 8% |

* Average cost-effectiveness ratio.
Fig. 2. a–c: Types of costs included in analyses.
interventions to implement. To improve consistency in the conduction and reporting of economic evaluations, an updated guideline is needed for interventions against viral pandemics.

Author statements

Ethical approval

None required.

Funding

MIKR and KK received unrestricted grants to conduct the scoping review from the Innovation Fund, Denmark.

Competing interests

The authors declare no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.puhe.2022.05.001.

References

1. Drummond MF, McGuire A. Economic evaluation in health care: merging theory with practice. Oxford: OUP; 2001.
2. Heinze E, Gerber-Grote A, Chahi B, Hamers FF, Rupel VP, Slabe-Erker R, et al. Is there a European View on health economic evaluations? Results from a Synthesis of methodological guidelines used in the EUnetHTA Partner countries. Pharmacoeconomics 2016;34(1):59–76.
3. Sharma D, Aggarwal AK, Downey LE, Pinja S. National healthcare economic evaluation guidelines: a Cross-country Comparison. Pharmacoeconomics - Open 2021;5(3):349–64.
4. Hawley SR, Thrivikraman JK, Noeck N, Romain TS, Ludy M-J, Barnhart L, et al. Concerns of college students during the COVID-19 pandemic: Thematic perspectives from the United States, Asia, and Europe. Journal of Applied Learning and Teaching 2021;4(1).
5. Ilsen C, van Veldhoven M, Kirchner K, Hansen JP. Six key Advantages and Disadvantages of working from home in Europe during COVID-19. Int J Environ Res Publ Health 2021;18(4):1826.
6. Grasso M, Klicperová-Baker M, Koos S, Kosyakova Y, Petrillo A, Vlase I. The impact of the coronavirus crisis on European societies. What have we learned and where do we go from here? – Introduction to the COVID volume. Eur Sociol Rev 2021;23(1):52–32.
7. Maliszewska M, Mattoo A, Van Der Mensbrugghe D. COVID-19 on GDP and trade: a preliminary assessment. Rev Econ Stud 2020;87(1):1–44.
8. Cutler DM, Summers LH. The COVID-19 pandemic and the $16 Trillion virus. JAMA 2020;324(15):1495–6.
9. OECD. OECD Economic Outlook. Interim report September 2021. https://www.oecd.org/
10. Asukai Y, Briggs A, Harrison JP, Rupel VP, Slabe-Erker R, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics 2016;34(3):227–44.
11. Yuasa A, Yonenomo N, Lo Presti M, Ikeda S. Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2021;21(2):235–45.
12. Davoudzadeh DM, Solomon KY. Cost-effectiveness of antiviral treatments for pandemics and outbreaks of Respiratory Illnesses, including COVID-19: a systematic review of published economic evaluations. Value Health 2020;23(11):1409–22.
13. Drummond MF, McGuire A. Economic evaluation in health care: merging theory with practice. Oxford: OUP; 2001.
14. Heintz E, Gerber-Grote A, Ghabri S, Hamers FF, Rupel VP, Slabe-Erker R, et al. Is there a European View on health economic evaluations? Results from a Synthesis of methodological guidelines used in the EUnetHTA Partner countries. Pharmacoeconomics 2016;34(1):59–76.
15. Maliszewska M, Mattoo A, Van Der Mensbrugghe D. COVID-19 on GDP and trade: a preliminary assessment. Rev Econ Stud 2020;87(1):1–44.
16. Deuffic-Burban S, Lenne X, Dervaux B, Julien P, Lemaire X, Sloan C, et al. Targeted vs. systemic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: clinical and economic impact. PLoS Curr 2009;1:Rnn121.
17. Du Z, Pandey A, Bai Y, Fitzpatrick MC, Chinazzi M, Pastore y, et al. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. Lancet Public Health 2021;6:183–91.
18. Elhage A, Ronnele C, Bartschgeilj E, van den Born B, Conover D, Klink C, Bruner J, et al. Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment. Endoscopy 2021;53(2):156–61.
19. Candau J-L. How Many Intensive care Beds are Justifiable for hospital Pandemic Preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Appl Health Econ Health Pol 2021;19:190–91.
20. Li R, Simmons KB, Bertolli J, Rivera-Garcia B, Cox S, Romero L, et al. Cost-effectiveness of increasing access to contraception during the Zika virus outbreak, Puerto Rico, 2016. Emerg Infect Dis 2017;23(1):74–82.
21. Reddy KP, Shelb FM, Fouta JHA, Harling G, Scott JA, Panella C, et al. Cost-effectiveness analysis of government strategies for COVID-19 epidemic control in South Africa. medRxiv; 2020.
22. Savitsky LM, Albright CM. Preventing COVID-19 transmission on labor and delivery: a decision analysis. Am J Perinatol 2020;37(1):1031–7.
43. Sheinso D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A cost-effectiveness framework for COVID-19 treatment in hospitalised patients in the United States. Adv Ther 2021;38:4:1811–33.

44. Shilov AI, Sheshno A, Sklan EH, Leshno M. Modeling social distancing strategies to Prevent SARS-CoV-2 Spread in Israel: a cost-effectiveness analysis. Value Health 2021;24:15:607–14.

45. Siddiqui MR, Edmunds WJ. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis 2008;14:2:267–74.

46. Vecino LVZ, Silva MT, Resende MR, de Silva EN, Galvao TF. Cost-effectiveness of movement restriction policies. Value Health 2021;24:4:615–24.

47. Venkatesan S, Carias C, Biggerstaff M, Campbell AP, Nguyen-Van-Tam JS, Razzak J, et al. Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: cost effectiveness analysis from Indian context. Clin Epidemiol Global Health 2021;10.

48. Wang X, Shen M, Xiao Y, Rong L. Optimal control and cost-effectiveness analysis of a Zika virus infection model with comprehensive interventions. Appl Math Comput 2019;359:165–85.

49. Wong ZS, Goldsman D, Tsui KL. Economic evaluation of individual school closure strategies: the Hong Kong 2009 H1N1 pandemic. PLoS One 2016;11:1:e0147052.

50. Xue Y, Kristiansen IS, De Blasio BF. Dynamic modelling of costs and health consequences of school closure during an influenza pandemic. BMC Public Health 2012;12:1.

51. You JH, Chan ES, Leung MY, Ip M, Lee NL. A cost-effectiveness analysis of “test” versus “treat” patients hospitalized with suspected influenza in Hong Kong. PLoS One 2012;7:3:e31123.

52. Zala D, Mosweu I, Critchlow S, ROMO R, McCRone P. Costing the COVID-19 pandemic: an exploratory economic evaluation of hypothetical suppression policy in the United Kingdom. Value Health 2020;23:1:1432–7.

53. Losina E, Leifer V, Millham L, Panella C, Hyle EP, Mohareb AM, et al. College Campuses and COVID-19 mitigation: clinical and economic value. Ann Intern Med 2021;174:4:472–83.

54. Risko N, Werner K, Offerjebbe OA, Vecino-Ortiz AI, Wallis LA, Razzaq J. Cost-effectiveness and return on investment of protecting health workers in low- and middle-income countries during the COVID-19 pandemic. PLoS One 2020;15:10.

55. Zhao J, Jin H, Li X, Jia J, Zhang C, Zhao H, et al. Disease Burden attributable to the first Wave of COVID-19 in China and the effect of timing on the cost-effectiveness of movement restriction policies. Value Health 2021;24:5:615–24.

56. Brown ST, Tai JH, Bailey RR, Cooley PC, Wheaton WD, Potter MA, et al. Would school closure for the 2009 H1N1 influenza epidemic have been worth the cost?: a computational simulation of Pennsylvania. BMC Public Health 2011;11:353.

57. Miles DK, Stedman M, Headl AH. Stay at home, Protect the National health service, Save Lives’: a cost benefit analysis of the lockdown in the United Kingdom. Int J Clin Pract 2021;75:3:e13674.

58. Thunström L, Newbold SC, Finnoff D, Ashworth M, Shogren JF. The benefits and costs of using social distancing to Flatten the Curve for COVID-19. J Benefit-Cost Anal 2020;11:2:179–95.

59. Wang B, Xie J, Fang P. Is a mass prevention and control program for pandemic (H1N1) 2009 good value for money? evidence from the Chinese experience. Iran J Public Health 2012;41:1:34–43.

60. Bajepally BS, Haridoss M, Natarajan M, Jeyashree K, Ponnaiah M. Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: cost effectiveness analysis from Indian context. Clinical Epidemiology and Global Health 2021;10.

61. Kamal MA, Smith PF, Chaiyakunapruk N, Wu DBC, Pratoomsoot C, Lee KKC, et al. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. Br J Clin Pharmacol 2017;83:7:1580–94.

62. Kellermarck B, Brouwer W, Van Baal P. Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone. Cost Eff Resour Allocation 2020;18:1.

63. Kolso JR, Halder N, Postma MJ, Milne GJ. Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories. BMC Public Health 2015;15:1.

64. Morales-Suárez-Varela M, Llopis-González A, González-Candelas F, Astry J, Alonso J, Carin O, et al. Economic evaluation of health services costs during pandemic influenza a (H1N1) Pdm09 infection in pregnant and non-pregnant women in Spain. Iran J Public Health 2016;45:4:243–34.

65. Tracht SM, Del Valle SY, Edwards BK. Economic analysis of the use of facemasks during pandemic (H1N1) 2009. J Theor Biol.300(5):161-172.

66. Carias C, Greening B, Campbell CG, Meltzer MI, Hanel MJ. Preventive malaria treatment for contacts of patients with Ebola virus disease in the context of the west Africa 2014-15 Ebola virus disease response: an economic analysis. Lancet Infect Dis 2016;16:4:409–98.

67. World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. No. WHO/2019-nCoV/c Clinical/2021.1. World Health Organization, 2021.

68. Aguas R, Mahdi A, Shresta R, Horby P, Landray M, White L, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun 2021;12:1:915.